Lv71
4970 积分 2022-01-22 加入
Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study
2小时前
已关闭
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
1个月前
已完结
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial)
1个月前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
1个月前
已完结
Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma
2个月前
已完结
A Systematic Literature Review of the Situation of the International Classification of Functioning, Disability, and Health and the International Classification of Functioning, Disability, and Health–Children and Youth Version in Education
2个月前
已完结
Impact of post‐progression survival in second‐line treatment with molecular target agents for unresectable hepatocellular carcinoma
2个月前
已完结
Three ways ChatGPT helps me in my academic writing
2个月前
已完结
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
3个月前
已完结
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
3个月前
已完结
皖公网安备34019202002308
